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Various tests for breast cancer tumor markers are used clinically to ostensibly aid earlier detection of 
breast cancer recurrence.  These tests, however, generally have poor sensitivity and have not been 
shown to improve survival.  Despite clinical guidelines recommending against their use for early-
stage cancer survivors, a substantial number of physicians still order these tests.  In order to quantify 
the use and associated costs of these tests, Dr. Scott Ramsey and colleagues in the Public Health 
Sciences Division evaluated SEER cancer registry records linked to Medicare claims data for tumor 
marker usage and medical care costs.  As recently reported in the Journal of Clinical Oncology, the 
authors found that 42% of early-stage breast cancer survivors received at least one tumor marker 
test for surveillance. Those who had these tests had 29% higher total medical care costs compared 
to those not receiving these tests. 
Both the American Board of Internal Medicine (ABIM) and the American Society of Clinical Oncology 
(ASCO) recommend against routine serial monitoring of tumor markers for breast cancer recurrence 
in early-stage breast cancer patients.  These recommendations are based on previous studies 
showing that use of tumor markers following treatment with curative intent does not improve survival 
in breast cancer patients.  These tests also have poor sensitivity, potentially leading to false positive 
results that drive downstream costs.  "Despite more than a decade of recommendations against their 
use," said lead author Dr. Ramsey, "we find that more than 40% of Medicare-enrolled breast cancer 
patients receive these tests." 
To quantify the costs associated with the use of these tests, the authors analyzed the Surveillance, 
Epidemiology, and End Results (SEER)-Medicare database from 2001-2007.  Focusing on tumor 
marker tests for carcinoembryonic estrogen and CA 15-3/CA 27.29, the authors analyzed all health 
care claims for breast cancer survivors within 2 years of diagnosis through billing codes.  Costs of 
care were measured as reimbursements for claims filed 3-24 months post-diagnosis.   
Of the nearly 40,000 eligible breast cancer patients identified during this period, the authors found 
that 42% had received at least one tumor marker test within two years of diagnosis.  The use of 
these tests had increased over time, from 38% of patients in 2001 to 46% of patients in  
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2007.  Younger women, those with more advanced SEER staging, and women living in rural areas 
were all more likely to undergo testing.  Overall, the total cost of care for those who received at least 
one test were 29% higher than for those not tested, an average of $6,500 more per patient.  The 
authors additionally found that rates of advanced imaging, but not rates of biopsies, were 
significantly higher in the group receiving tumor marker tests, suggesting many of these tests 
reported recurrences that turned out to be false positives. 
"Our study highlights the fact that substantial savings can be achieved in oncology without harming 
patients," said Dr. Ramsey.  "Given the financial strains that oncology patients and providers are 
facing today, discontinuing routine use of breast cancer tumor markers in this setting should be a no-
brainer.  The Hutchinson Institute for Cancer Outcomes Research (HICOR) is committed to help 
doctors and patients understand the implications of testing, and to help change this practice." 
Despite these findings, however, holdouts remain.  Said co-author Dr. Julie Gralow, "there are still 
many oncologists ordering these tests, which would likely indicate that they don’t agree with ASCO’s 
recommendation and that the issue has not been settled with clear evidence."  In a companion 
commentary published in the Journal of the National Cancer Institute, several of the authors call for 
clinical trials that could definitively settle the issue (see citation).  Said Dr. Gralow, "while there is not 
evidence that shows that earlier detection of breast cancer recurrence improves survival, there are 
no modern era trials using current treatments and imaging technology."  
As such, the authors are trying to set up a large study funded to evaluate these questions.  "The 
study would ask a lot of questions about long-term breast cancer survivorship—a WHI-type trial for 
breast cancer survivors," said Dr. Gralow.  If funded, such evidence would help in identifying optimal 
breast cancer follow-up strategies and bringing clinician beliefs in line with practice guidelines, a win-
win for healthcare costs and treatment.  
Other PHS investigators contributing to this project were Drs. Dana Mirick, William Barlow, Ruth 
Etzioni, and David Mummy. 
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Image designed by Dr. Catherine Richards 
Percentage increase in total costs of care among patients 
receiving at least one tumor marker test relative to those with no 
tumor marker tests, by time period after diagnosis. Light gray 
area indicates the 95% confidence interval around the estimate; 
both percentages are statistically significant (P < 0.001). 
 
